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1084Objective: We sought to describe early outcomes of aortic valve replacement in neonates and infants across
a large multicenter cohort.
Methods: Neonates and infants in the Society of Thoracic Surgeons Congenital Heart Surgery Database under-
going nontruncal aortic valve replacement with the Ross-Konno procedure, Ross procedure, or homograft re-
placement from 2000 to 2009 were included. Preoperative characteristics, operative data, and early outcomes
are described.
Results: A total of 160 patients (43 neonates, 117 infants) from 47 centers were included. Society of Thoracic
Surgeons–defined preoperative risk factors were present in 76 patients (48%) and were most prevalent in neo-
nates (67%) and patients undergoing homograft aortic valve replacement (93%). Concomitant arch repair or
mitral valve surgery was performed in 30 patients (19%) and 19 patients (12%), respectively. Postoperative me-
chanical circulatory support was used in 17 patients (11%). Overall in-hospital mortality was 18% and was
highest for neonates (28%) and patients undergoing homograft aortic valve replacement (40%). Concomitant
arch repair was associated with higher in-hospital mortality (33% vs 15%, P¼ .02), whereas concurrent mitral
valve surgery was not (21% vs 18%, P¼ .73). Postoperativemechanical circulatory support was also associated
with increased in-hospital mortality (65% vs 13%, P<.0001).
Conclusions: Neonates and infants undergoing aortic valve replacement are a high-risk group, with hospital
mortality comparable with some of the highest risk procedures in this age group. The requirement for arch repair
or postoperative mechanical circulatory support was associated with an increased risk of death in this cohort.
(J Thorac Cardiovasc Surg 2012;144:1084-90)Aortic valve replacement (AVR) in neonates and infants is
generally reserved for those instances when more conserva-
tive surgical procedures or catheter-based interventions
have been unsuccessful or offer little chance of achieving
an acceptable hemodynamic outcome. Because of the rarity
of AVR in very young children, previous reports of out-
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The Journal of Thoracic and Cardiovascular Surinfants. The largest multi-institutional report evaluating
the Ross or Ross-Konno procedure in this population in-
cluded 33 patients<3 years of age, of which 12 were neo-
nates.1 The largest single-institution report included 31
infants, of which 16 were neonates.2 Numerous other re-
ports describe individual center’s experiences with 1 or
more technique of AVR in the pediatric age group, but offer
little information specific to neonates or infants.3-17
Contemporary benchmark data based on a larger multi-
center cohort of neonates and infants undergoing AVR
could potentially improve our understanding of outcomes
in this challenging group of patients. We therefore sought
to describe characteristics and outcomes for neonates and
infants undergoing AVR across a large multi-institutional
cohort using the Society of Thoracic Surgeons (STS)
Congenital Heart Surgery Database.PATIENTS AND METHODS
Data Source
The STS Congenital Heart Surgery Database is the largest pediatric
heart surgery registry in the world and currently contains information on
>200,000 children undergoing heart surgery in North America since
1998. Perioperative, operative, and outcomes data are collected on all chil-
dren undergoing heart surgery at participating centers. Data quality are
evaluated through intrinsic verification of data and a formal process ofgery c November 2012
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Dsite visits and data audits.18 The Duke Clinical Research Institute serves as
the data warehouse and analytic center for all the STS national databases.
This study was approved by the Duke University Medical Center institu-
tional review board, with waiver of informed consent, and by the Access
and Publications Committee of the STSWorkforce on National Databases.
Patient Population
The study population included patients 1 year of age undergoing an
index operation of the Ross-Konno procedure, Ross procedure, or homo-
graft AVR from 2000 to 2009. These inclusion criteria were met by 215 pa-
tients from 51 centers. Patients with missing data (n ¼ 51) and those with
a diagnosis of truncus arteriosus (n ¼ 4) were excluded. Although the STS
database contains nearly complete data for the standard core data fields re-
quired to calculate in-hospital mortality, not all centers submit complete
data for all variables, such as patient preoperative characteristics or postop-
erative complications. Therefore, it is standard practice to exclude centers
with>15%missing data for key study variables to maximize data integrity
and minimize missing data.
Data Collection
Patient characteristics included age at surgery, gender, surgery weight,
any noncardiac/genetic abnormalities, and any STS-defined preoperative
risk factors. Operative variables included cardiopulmonary bypass time,
aortic crossclamp time, and other procedures performed at the time of aor-
tic valve surgery such as mitral valve surgery (any type of mitral valve re-
pair or replacement) or aortic arch repair (all methods of repair of aortic
arch hypoplasia, interrupted aortic arch, or coarctation of aorta) with or
without ventricular septal defect repair. Some details of type of arch repair
(graft augmentation and so forth) were not captured consistently in the da-
tabase and therefore were not analyzed.
Outcomes
The primary outcome measure was in-hospital mortality. Secondary
outcome measures included postoperative length of stay and occurrence
of postoperative complications as defined in the STS database, including
postoperative mechanical circulatory support.19
Statistical Analysis
Study population characteristics and outcomes were described overall
and across surgical and age groups (neonates, 0-30 days; infants, 31-365
days) using standard summary statistics. In recognition of the likelihood
that certain anatomic and patient factors that may affect outcome in this co-
hort are not captured in the database, we focused on a descriptive analysis;
formal statistical comparisons of outcomes in patients undergoing Ross,
Ross-Konno, and homograft AVR were not made. The impact of concom-
itant procedures (aortic arch repair or mitral valve surgery) and postopera-
tive mechanical circulatory support on outcomewas evaluated using the c2
test. All analyses were performed using SAS version 9.2 (SAS Institute Inc,
Cary, NC). A P value<.05 was considered statistically significant.RESULTS
The study cohort consisted of 160 patients from 47 cen-
ters. Overall, 101 patients (63%) underwent the Ross-The Journal of Thoracic and CarKonno procedure, 44 patients (28%) underwent the Ross
procedure, and 15 patients (9%) underwent homograft
AVR. Neonates and infants comprised 27% and 73% of
the cohort, respectively.
Preoperative Characteristics
Table 1 summarizes the preoperative characteristics
of the cohort. Median weight at surgery was 3.2 kg (z score,
0.9) for neonates and 5.4 kg (z score,1.6) for infants. Val-
var and/or subvalvar aortic stenosis was the most common
primary diagnosis in all procedural and age groups whereas
16% of neonates and 22% of infants were coded as having
a primary diagnosis of aortic insufficiency or combined ste-
nosis and insufficiency. STS-defined risk factors were pres-
ent in 76 patients (48%) and were most prevalent in
neonates (67%) and patients undergoing homograft AVR
(93%). Preoperative mechanical ventilation was common.
Preoperative shock or acidosis was less frequent, although
it occurred in 20% of patients undergoing homograft
AVR. No patient received preoperative mechanical circula-
tory support.
Operative Characteristics
The Ross-Konno procedure was the most prevalent pro-
cedure in both age groups, followed by the Ross procedure.
Homograft replacement was relatively uncommon in both
age groups (Table 1). Table 2 summarizes the operative
data. Cardiopulmonary bypass times were generally similar
across procedure types, although were slightly longer for
the Ross-Konno procedure. Concomitant mitral valve sur-
gery was performed in 19 patients (12%), including 16%
of neonates and 10% of infants. Among patients undergo-
ing the Ross-Konno procedure, 14% had concomitant mi-
tral valve surgery. Concomitant arch/coarctation repair
was performed in 30 patients (19%), including 40% of ne-
onates and 11% of infants. Among patients undergoing the
Ross-Konno procedure, 25% had concomitant arch/coarc-
tation repair.
Postoperative Outcomes
Table 3 summarizes early postoperative outcomes.
In-hospital mortality in the overall cohort was 18%, and
was 28% in neonates versus 14% in infants. Of the 3 pro-
cedure groups, those who underwent homograft AVR had
the highest mortality rate (40%). Thirteen patients experi-
enced postoperative cardiac arrest, including 9% of neo-
nates and 8% of infants. Seventeen patients received
postoperative mechanical circulatory support, including
19% of neonates and 8% of infants. In the Ross-Konno pro-
cedure group, 12% of patients received postoperative me-
chanical circulatory support. For the entire cohort, other
major adverse outcomes included unplanned reoperation
in 5.6%, reoperation for bleeding in 4.4%, renal failure re-
quiring temporary or permanent dialysis in 4.4%, anydiovascular Surgery c Volume 144, Number 5 1085
TABLE 1. Preoperative characteristics
Characteristic Overall (n ¼ 160) Ross-Konno (n ¼ 101) Ross (n ¼ 44) Homograft (n ¼ 15)
Age, d, median (IR) 87 (23-185) 63 (16-194) 96 (52-171) 98 (79-171)
Age category, n (%)
Neonates 43 (27) 35 (35) 7 (16) 1 (7)
Infants 117 (73) 66 (65) 37 (84) 14 (93)
Weight, kg, median (IR)
Overall 4.8 (3.6-6.4) 4.0 (3.4-6.2) 5.2 (4.4-7.0) 4.8 (4.3-5.4)
Neonates 3.2 (2.9-3.7) 3.2 (3.0-3.7) 3.3 (2.8-4.1) 2.7 (2.7-2.7)
Infants 5.4 (4.4-6.9) 5.5 (3.9-6.9) 6.0 (5.1-7.2) 4.9 (4.5-5.4)
Weight-for-age z score, median (IR)
Overall 1.3 (2.1 to0.5) 1.4 (2.2 to0.7) 1.0 (1.9 to 0.2) 1.7 (3.0 to1.2)
Neonates 0.9 (1.5 to 0.1) 0.9 (1.3 to 0.0) 0.5 (1.5 to 0.5) 2.1 (2.1 to2.1)
Infants 1.6 (2.2 to0.8) 1.7 (2.4 to1.1) 1.1 (1.9 to0.1) 1.7 (3.0 to1.2)
Non-CV/genetic abnormality, n (%)
Overall 33 (21) 24 (24) 6 (14) 3 (20)
Neonates 7 (16) 7 (20) 0 (0) 0 (0)
Infants 26 (22) 17 (26) 6 (16) 3 (21)
STS-CHSD risk factors
Any risk factor, n (%)
Overall 76 (48) 47 (46) 15 (34) 14 (93)
Neonates 29 (67) 22 (63) 6 (86) 1 (100)
Infants 47 (40) 25 (38) 9 (24) 13 (93)
Mechanical ventilation, n (%)
Overall 42 (26) 29 (29) 7 (16) 6 (40)
Neonates 19 (44) 15 (43) 3 (43) 1 (100)
Infants 23 (20) 14 (21) 4 (11) 5 (36)
Shock or acidosis, n (%)
Overall 13 (8) 9 (9) 1 (2) 3 (20)
Neonates 4 (9) 4 (11) 0 (0) 0 (0)
Infants 9 (8) 5 (8) 1 (3) 3 (21)
Previous cardiac surgery, n (%)
Overall 49 (31) 32 (32) 11 (25) 6 (40)
Neonates 3 (7) 1 (3) 2 (29) 0 (0)
Infants 46 (39) 31 (47) 9 (24) 6 (43)
Data are presented as median and interquartile range for continuous variables, and number and percent for dichotomous variables. IR, Interquartile range; CV, cardiovascular;
STS-CHSD, Society of Thoracic Surgeons Congenital Heart Surgery Database.
Congenital Heart Disease Woods et al
C
H
Dpostoperative neurologic deficits in 2.5%, and heart block
requiring permanent pacemaker in 1.9% of patients. Me-
dian postoperative length of stay in the overall cohort was
12 days, and was 20 days for neonates versus 10 days for
infants.
In the overall cohort, concomitant arch repair was associ-
ated with significantly higher in-hospital mortality (33% vs
15%, P ¼ .02). In contrast, concomitant mitral valve
surgery was not associated with a statistically significant
difference in mortality (21% vs 18%, P ¼ .73). Postopera-
tive mechanical circulatory support was also associated
with significant in-hospital mortality (65% vs 13%,
P<.0001).
COMMENT
This analysis of a large multi-institutional cohort of neo-
nates and infants undergoing AVR from the STS Congenital
Heart Surgery Database demonstrates that AVR in neonates
and infants is associated with high rates of in-hospital1086 The Journal of Thoracic and Cardiovascular Surmortality—28% in neonates and 14% in infants. To put
these figures in perspective, evaluation of a recent harvest
report from the STS Congenital Heart Surgery Database
(2007 to 2010) reveals that the mortality associated with
neonatal AVR ranks among the highest of all procedure-
specific mortality rates in this age group (arterial switch
with arch repair, 18.2%; stage 1 Norwood, 17.6%; Eb-
stein’s repair, 30.2%).20 For infants, in-hospital mortality
associated with AVR ranks in a similar manner (hybrid
stage 2, 22.6%; scimitar, 14.3%; right/left heart assist de-
vice, 14%).20
The results of our study are considered in the context of
recent single-center reports from institutions with signifi-
cant experience managing neonates and infants with critical
left ventricular outflow obstruction. In the largest single-
center series, Shinkawa and colleagues2 reported 31
patients (16 neonates) who underwent the Ross or Ross-
Konno procedure during the first year of life. Early mortal-
ity was 16%. Of note, in that series, all early mortalitygery c November 2012
TABLE 2. Operative characteristics
Characteristic Overall (n ¼ 160) Ross-Konno (n ¼ 101) Ross (n ¼ 44) Homograft (n ¼ 15)
CPB time, min, median (IR)
Overall 202 (150-270) 212 (159-280) 192 (136-249) 196 (133-226)
Neonates 226 (152-293) 226 (157-293) 228 (152-386) 129 (129-129)
Infants 198 (149-258) 210 (160-271) 189 (136-224) 200 (135-226)
Clamp time, min, median (IR)
All ages 132 (96-167) 143 (106-174) 118 (74-156) 108 (86-139)
Neonates 138 (88-182) 132 (92-182) 148 (87-188) 86 (86-86)
Infants 131 (100-162) 145 (111-173) 116 (63-144) 118 (91-139)
Concurrent arch repair, n (%)
Overall 30 (19) 25 (25%) 4 (9%) 1 (7%)
Neonates 17 (40) 15 (43) 2 (29%) 0 (0%)
Infants 13 (11) 10 (15%) 2 (5%) 1 (7%)
Concurrent mitral surgery, n (%)
Overall 19 (12) 14 (14) 3 (7) 2 (13)
Neonates 7 (16) 5 (14) 2 (29) 0 (0)
Infants 12 (10) 9 (14) 1 (3) 2 (14)
Data are presented as median and interquartile range for continuous variables, and number and percent for dichotomous variables.CPB, Cardiopulmonary bypass; IR, interquartile
range.
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comitant surgery on the aortic arch or mitral valve. The
early mortality rate of 0 among the 17 patients who required
neither arch nor mitral valve repair makes that series unique
with respect to our multi-institutional report and to other
published single-institution series. Another single-center
report from Alsoufi and associates3 described outcomes
among 21 patients (8 neonates, 13 infants) who underwent
Ross or Ross-Konno procedures. More than half of patients
had undergone prior intervention on the aortic valve or aor-
tic arch. Mortality was 19% at 1 month and 30% at 1 year.3
Similar to the results of our study, a recent Congenital Heart
Surgeons Society multicenter study by Hickey and co-
workers1 reported somewhat higher mortality rates com-
pared with previous single-center studies. Their study
included 13 patients with the Ross procedure and 26 pa-
tients with the Ross-Konno procedure (12 neonates and 8
additional patients<3 months of age). Survival for these
39 patients was 74  7%, 67  8%, and 67  8% at 1,
5, and 7 years, respectively, with 80% of deaths occurring
within 2 months of surgery.1
Although highly experienced teams at several institutions
have achieved good outcomes with appropriately selected
patients, outcomes reported from both the STS database
and from the Congenital Heart Surgeons Society research
database indicate that neonates and infants who require
AVR are, overall, a high-risk group. This is perhaps not un-
expected, in light of some of the issues that characterize this
specific patient population—challenging and often dire
clinical circumstances requiring AVR at such a young
age, prior interventions, the multilevel nature of left-sided
obstructive disease, the complexity and magnitude of the
surgical procedures, and/or the challenge in certain patients
of predicting suitability for a 2-ventricle repair.The Journal of Thoracic and CarOur observation that the Ross-Konno procedure was the
most frequently performed of the 3 types of AVR (81%
of neonates and 56% of infants) is undoubtedly related to
the multilevel nature of left-sided obstructive disease pre-
senting during the first year of life. Even in patients with
predominantly valvar disease, it is often necessary to en-
large the annulus to accommodate an appropriately sized
valve substitute. In the 2 series reported by Shinkawa and
colleagues2 and Alsoufi and associates,3 the frequency of
annular enlargement (Ross-Konno procedure) was 25/31
(81%) and 14/21 (67%), respectively. Our finding that
40% of patients in the Ross-Konno group underwent con-
comitant surgery on the mitral valve or aortic arch supports
further the multilevel nature of left-sided disease in this age
group. Corresponding figures from the series by Shinkawa
and colleagues2 and Alsoufi and associates3 are similar to
ours—14/31 (45%) and 10/21 (48%), respectively.
Our finding of a particularly high rate of mortality in the
homograft AVRgroup (40% in the homograft AVRgroup vs
9% in the Ross procedure group) standswithout comparison
in the literature because, to our knowledge, there are no prior
reports comparing homograft AVR with the Ross procedure
in infants. AlthoughNajm and coworkers17 reported in 1999
on a series of 30 children who underwent valve replacement
with an aortic allograft (22 patients) or pulmonary autograft
(8 patients), the mean age was 5.4 years. Only eight patients
were infants. Nearly all deathswere in patients<2months of
agewith acute aortic insufficiency after balloon angioplasty.
When considering factors in our cohort that could have
influenced the choice of homograft replacement, a substan-
tial difference in morphology of the left ventricular outflow
tract between the 2 groups seems unlikely, because both pro-
cedures are generally used to address similar anatomic sub-
strates. Abnormality of the pulmonary valve is also andiovascular Surgery c Volume 144, Number 5 1087
TABLE 3. Early postoperative outcomes
Outcome
Overall
(n ¼ 160)
Ross-Konno
(n ¼ 101)
Ross
(n ¼ 44)
Homograft
(n ¼ 15)
In-hospital mortality,
n (%)
Overall 29 (18) 19 (19) 4 (9) 6 (40)
Neonates 12 (28) 10 (29) 2 (29) 0 (0)
Infants 17 (14) 9 (14) 2 (5) 6 (43)
Cardiac arrest, n (%)
Overall 13 (8) 9 (9) 2 (5) 2 (13)
Neonates 4 (9) 2 (6) 1 (14) 1 (100)
Infants 9 (8) 7 (11) 1 (3) 1 (7)
Mechanical circulatory
support, n (%)
Overall 17 (11) 12 (12) 3 (7) 2 (13)
Neonates 8 (19) 6 (17) 2 (29) 0 (0)
Infants 9 (8) 6 (9) 1 (3) 2 (14)
Length of stay, d,
median (IR)
All ages 12 (6-26) 15 (8-28) 8 (5-14) 10 (5-28)
Neonates 20 (14-39) 20 (15-39) 17 (9-72) 75 (75-75)
Infants 10 (6-19) 11 (7-25) 7 (5-13) 10 (5-23)
Data are presented as median and interquartile range for continuous variables, and
number and percent for dichotomous variables. IR, Interquartile range.
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tic valve surgery rarely have significant pulmonary valve
disease. We did observe a significantly higher prevalence
of certain preoperative risk factors in the homograft replace-
ment group. It is plausible that unfavorable preoperative sta-
tus may have influenced the selection of procedure type
(homograft replacement perhaps being considered a more
expedient option for the sicker patients) and may have ex-
erted an influence on outcome. In view of the limited preop-
erative anatomic and physiologic information captured
currently in the database, and the small number of patients
in the homograft group even in this multicenter data set, de-
tailed risk-adjusted comparison of procedure types was not
able to be performed. Although the observed 4-fold higher
mortality associatedwith homograft AVRwithin the context
of comparable cardiopulmonary bypass times does raise
questions concerning the comparative ‘‘expediency’’ of ho-
mograft AVR and its effectiveness at offsetting risk, the ac-
tual reasons for the high rate of operative mortality are
a matter of speculation. During the study era, procedures
coded in the STS Congenital Heart Surgery Database were
not classified with respect to urgency, (elective, urgent, sal-
vage), so no inferences can be drawn reliably concerning the
relative urgency of homograft AVRs.
Previous reports emphasizing outcomes in the neonatal or
infant population have cited various risk factors for mortal-
ity—younger age, associated arch or mitral valve disease,
emergency presentation with severe aortic insufficiency
after balloon dilatation, duration of cardiopulmonary
bypass and/or myocardial ischemia, postoperative1088 The Journal of Thoracic and Cardiovascular Surmechanical circulatory support, and suitability for biventric-
ular repair.1-3,5,6,14,15,17,21-23 Although risk factor analysis
was not a primary objective of our study because of the
nature of the database, we did observe higher mortality in
neonates in comparison with infants. Mortality was also
higher in patients who had concomitant arch repair or
received postoperative mechanical circulatory support.
Limitations
Although this study provides a contemporary, multi-
institutional perspective of patterns of practice and out-
comes in this high-risk group of surgical patients, it is
subject to constraints inherent to observational studies and
the nature of the STS Congenital Heart Surgery Database.
To preserve integrity of the data, nearly one third of patient
records were excluded. However, mortality in this group of
patients was evaluated and was similar to the mortality of
patients included in the report. We also acknowledge that
a data set limited to patients treated with AVR precludes
making inferences about the appropriateness of biventricu-
lar repair or the superiority of valve replacement over other
surgical or catheter-based interventions. During the study
period, the STS Congenital Heart Surgery Database did
not collect consistently certain types of information that
would permit more thorough characterization of preopera-
tive status (prior surgical or catheter-based interventions,
hemodynamic data, echocardiographic or angiographic
data, and emergency/urgent/elective status of the proce-
dure). Therefore, the nature of the data set precluded the
possibility of undertaking multivariable analyses to exam-
ine potential independent associations among patient fac-
tors, procedure type, and early outcome. Likewise, lack of
follow-up data precluded evaluation of reintervention rates
and longer term outcomes. Recent and currently planned
improvements in the STS Congenital Heart Surgery Data-
base include expansion of the patient-level data pertinent
to preoperative status, as well as important historical infor-
mation including history of previous catheter-directed bal-
loon valvotomy. The implementation of these changes
will address some of the limitations of the current study,
thereby improving substantially the versatility and utility
of the database for future investigations.
CONCLUSIONS
AVR in neonates and young infants is associated with
substantial mortality, ranking among the highest risk of
all cardiac procedures in these age groups. Amajority of ne-
onates undergo procedures additionally directed at the aor-
tic subvalvar outflow tract, aortic arch, or mitral valve.
Neonatal age, arch repair, and postoperative mechanical
circulatory support are associated with increased risk of
death. A multi-institutional effort based on a patient and
disease-oriented approach may lead to an improved under-
standing of both patient selection and the role of medical,gery c November 2012
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Dcatheter-based, and/or surgical intervention in the manage-
ment of these challenging patients.
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Dr Christopher Caldarone (Toronto, Ontario, Canada). Dr
Woods, my congratulations on an excellent presentation. This
study is very important because it clearly demonstrates the value
of widely adopted registries like the STS database, and not surpris-
ingly, you have shown that the mortality rate for these procedures
is much higher than in single-center reported series, which we all
know are biased toward reporting favorable results, and therein I
suspect lies the most important message of your study. The price
for this broad perspective, however, is an inevitable loss of detail,
and this is where I would like to ask a few questions.
Forty percent of the infants in your series underwent surgical
procedures prior to the index procedure described in your analy-
sis. In addition, there is some unknown number of cardiology-
based procedures that also may have been performed. For those
in the audience not familiar with this particular problem, patients
with left ventricular outflow tract obstruction commonly have as-
sociated lesions at the mitral, ventricular, valvar, and aortic arch
levels. Can you shed some more light on the impact of these pre-
operative procedures on the procedure-based cohort you have
described?
Dr Woods. Thank you for your question, Dr Caldarone. To ad-
dress the issue of procedures either prior to or subsequent to the
aortic valve replacement procedure with the STS database would
require both a combination of linkage potentially across multiple
admissions as well as a greater level of granularity in the data per-
taining to additional procedures, particularly catheter-based
procedures.
And as you are probably aware, the upgrade schedule for the da-
tabase in January of next year will have some important changes. It
will include diagnostic codes that include status postprocedural
codes to provide additional procedural information. It will also
permit linkage not only across admissions, but also to potential
other sources of data and, in particular, the IMPACT registry of
the American College of Cardiology. So with these changes I
think, in the future, it should be possible to address some of these
issues that you bring up.
What we are left with at present is what has been published, and
certainly you and your colleagues from the Congenital Heart Sur-
geons Society I believe published in the European Journal of Car-
diothoracic Surgery in 2010 and more recently this year in
February in the Journal of Thoracic and Cardiovascular Surgery
regarding some of these issues. Based on those results, multiple
procedures are not uncommon and overall survival appears to be
compromised by the cumulative procedural risk.
Dr Caldarone. You reported that concomitant aortic arch sur-
gery is associated with higher mortality, suggesting that greater
left-sided hypoplasia is associated with more mortality. Surpris-
ingly, concomitant mitral surgery was not a risk factor for death.
Do you suspect that we as a profession have successfully neutral-
ized the mitral valve issue or are we simply getting better at iden-
tifying irreparable mitral anomalies and shunting these patients
into a single ventricle pathway, an event that would not be detected
in your analysis?
Dr Woods. What you imply or suggest may be true, but our
study wasn’t designed to look at temporal trends and outcomes
with concomitant mitral surgery nor in improvements in patient se-
lection. I acknowledge the manuscript that you and yourdiovascular Surgery c Volume 144, Number 5 1089
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Dcolleagues from Toronto published I believe in the Annals of Tho-
racic Surgery recently in which you evaluated mitral surgery ver-
sus no mitral surgery in the Ross-Konno group. Clearly, there was
higher mortality with concomitant mitral surgery. I don’t need to
cite your own data to you, you know it very well, but for the
sake of the audience, as I recall, there were 8 patients who had mi-
tral surgery and their median age was approximately 300 days. For
the group that didn’t havemitral surgery, therewere approximately
12 patients, and their median age approached almost 6 years. That
is considerably older than the group of patients with concomitant
mitral surgery in the current cohort. To the extent that is relevant, I
don’t know. In the study from Ann Arbor, mortality occurred ex-
clusively in patients who had either concomitant arch or mitral sur-
gery, but actually I think there were only 2 patients in that study
who had concomitant mitral surgery.
From an intuitive standpoint I think many of us, myself in-
cluded, would be expecting higher mortality with concomitant sur-
gery. The cohort we present today certainly has the largest number
of patients with concomitant mitral surgery, but that doesn’t really
answer the issue because we don’t know for those patients in the
current cohort who didn’t have mitral surgery, the degree to which
they were actually free of mitral valve disease, and I think without
that information it is hard to really know the true answer. So I think
it is an unresolved issue.
Dr Caldarone. Well, like all good studies, you have raised
more questions than you have answered. So I congratulate you
and urge you and your colleagues to continue studying this very
interesting cohort.
Dr Vaughan Starnes (Los Angeles, Calif). Dr Woods, thank
you for the information that you have just presented. I am going
to ask you to speculate. Given that the mortality and the complica-
tions with homograft insertions are equal to that of the Ross pro-
cedure, and knowing the limited survival rate of those1090 The Journal of Thoracic and Cardiovascular Surhomografts in infants, anywhere from 5 months to 1 year durabil-
ity, would you say that homografts are still indicated in that age
group?
Dr Woods. Thank you for your question, Dr Starnes. I don’t
think our data really answer that question. In an elective setting
for aortic stenosis, with rare exception, the Ross procedure would
seem to be the preferred approach. For those patients who present
acutely with wide-open insufficiency in a really compromised
state, it may be that their early outcomes are defined more by
the presenting physiologic condition as opposed to the type of pro-
cedure. It is a difficult question and I am not certain I have an an-
swer for you, Dr Starnes.
Dr Starnes. Thank you.
Dr Emile Bacha (New York, NY). Ron, a great talk. Thank you
for pointing out the hard, cold fact that these patients have a high
mortality and comparing them with other high-mortality proce-
dures that we do, such as the Norwood procedure. I would like
to have your impression on whether this is not maybe a judgment
problem rather than a technical problem. We can do AVRs in ne-
onates, but it should be a very rare procedure, and so the question
is really whether some of these patients shouldn’t have had anAVR
and rather gone down the single ventricle route.
Dr Woods. That is really the home run question, I think, Dr
Bacha, as you point out. Certainly, early survival is the first goal,
and based on the present cohort, a neonatal Ross-Konno appears
to have a higher mortality than a stage 1 Norwood. I think when
confronted at the bedside with a patient and one is considering
a single versus a biventricular strategy, if that patient has disease
at more than just the valvar and subvalvar levels, particularly if
the ventricle is on the smaller side and/or some degree of endocar-
dial fibroelastosis is present, I think one would be very prudent to
think long and hard before pushing that patient down an initial bi-
ventricular pathway.gery c November 2012
